段嘉伦
副教授
E-mail：jialun.duan@njucm.edu.cn
主要研究方向：
基于中药多糖的疫苗佐剂开发与创新药物研究；药食同源资源的功效挖掘与大健康产品开发
个人简介

1.Bao CJ1, Liu MQ1, Liu YN1, Zhao LQ1, Li YX, Zhang XL, Zhang F, Guo S, Shang EX, Duan JL*, Duan JA*. A structurally distinct arabinose-bridged arabinogalactan from Lycium barbarum as a TLR4-activating adjuvant for nanovaccine-based cancer immunotherapy. Carbohyd Polym. 2026, 373: 124618. (中科院一区，IF=12.5)

2.Zhang J1, Bao CJ1, Zhang XL, Ren YH, Zhao W, Zhang F, Guo S, Duan JA*, Duan JL*, Han X*. Lycium barbarum polysaccharide-based hydrogel as a novel oral colon-targeted drug delivery system for enhanced MSS-CRC treatment by macrophage lipid reprogramming. Adv Funct Mater. 2026: e23769. (中科院一区，IF=19.0)

3.Yao AN1, Liang XF1, Wang ZF, Sha DP, Zhang XL, Liu MQ, Zhao LQ, Liu YN, Guo S, Zhang F, Bao CJ*, Duan JA*, Duan JL*. Acidic Lycium barbarumpolysaccharide as a promising candidate for preventing osteosarcopenia. Food Sci Hum Well. 2026, 15: 9250549. (中科院一区，IF=7.4)

4.Zhao LQ1, Li ZQ1, Liu YF1, Jiang MT1, Liu YN, Zhang XL, Sun YJ, Duan JL*, Bao CJ*, Duan JA*. Ultrasonic complexation with Lycium barbarumpolysaccharide significantly enhances the aqueous solubility and bioavailability of curcumin. Ultrasonics Sonochemistry. 2025, 123: 107673. (中科院一区，IF=9.7)

5.Duan JL1, Zhang XL1, Zhao LQ, Liu YN, Yao AN, Li NG, Duan JA, Bao CJ. Macrophage membrane-camouflaged nanoparticles for targeted drug delivery. Chinese Chem Lett. 2025, 111610. （中科院一区，IF=8.9）

6.Liu MQ1, Bao CJ1, Liang XF, Ji XY, Zhao LQ, Yao AN, Guo S, Duan JL*, Zhao M*, Duan JA*. Specific molecular weight of Lycium barbarum polysaccharide for robust breast cancer regression by repolarizing tumor-associated macrophages. Int J Biol Macromol. 2024, 261 : 129674. （中科院二区，IF=8.5）

7.Duan JL1, Liu MQ1, Liu YN1, Liang XF, Cao C, Yao AN, Zhao LQ, Guo S, Qian DW, Bao CJ*, Zhao M*, Duan JA*. Comparative study on physicochemical characterization and immunomodulatory activities of neutral and acidic Lycium barbarum polysaccharides. Biomed Pharmacother. 2024, 181: 117659. （中科院二区，IF=6.9）

8.Bao CJ1, Duan JL1, Xie Y1, Feng XP, Cui W, Chen SY, Li PS, Liu YX, Wang JL, Wang GL, Lu WL*. Bioorthogonal engineered virus-like nanoparticles for efficient gene therapy. Nanomicro Lett. 2023, 15(1): 197. （中科院一区，IF=31.6）

9.Chen Y1, Bao C1, Duan J1, Xie Y*, Lu W*. Overcoming biological barriers by virus-like drug particles for drug delivery. Adv Drug Deliver Rev. 2023, 203: 115134. （中科院一区，IF=16.1）

10.Duan JL1, Bao CJ1, Xie Y1, Guo HT, Liu YX, Li JW, Liu R, Li PS, Bai J, Yan Y, Mu LM, Li XQ, Wang GL, Lu WL*. Targeted core-shell nanoparticles for precise CTCF gene insert in treatment of metastatic breast cancer. Bioact Mater. 2022, 11: 1-14. （中科院一区，IF=18.9）

科研项目

1. 基于“扶正祛邪”理论的中药来源糖类候选药物发现及其在恶性肿瘤治疗中的作用机制研究（2025YFC3512200），国家重点研发计划青年科学家项目，2025/11-2028/10，60/200万，主持（任务负责人），在研

2. 枸杞多糖作为原位肿瘤疫苗的新型佐剂增强抗胰腺癌免疫应答研究（82405025），国家自然科学基金青年科学基金项目（C类），2025/01-2027/12，30万元，主持，在研

3. 江苏省“双创博士”人才项目（JSSCBS20230146），2024/01-2025/12，19.2万元，主持，结题

4. 精制枸杞多糖作为高效佐剂的中药肿瘤疫苗用于黑色素瘤免疫治疗研究（BK20230462），江苏省自然科学基金，2023/09-2026/08，20万元，主持，在研

5. 鸦胆子苦醇-枸杞多糖原位疫苗抗胰腺癌效应与机制研究（23KJB360010），江苏省高等学校基础科学(自然科学)研究面上项目（A类资助），2023/07-2025/06，5万元，主持，结题

6. 中药多糖作为疫苗佐剂的抗肿瘤效应与机制研究（ZDXM-2023-17），江苏省中药资源产业化过程协同创新中心开放课题重点项目，2023/09-2025/08，40万元，主持，结题

7. 中药资源循环利用关键技术研发及产业化示范（2025YFC3509100），国家重点研发计划，2025/11-2029/10，1000万元，参与，在研

代表性论文

1.Bao CJ1, Liu MQ1, Liu YN1, Zhao LQ1, Li YX, Zhang XL, Zhang F, Guo S, Shang EX, Duan JL*, Duan JA*. A structurally distinct arabinose-bridged arabinogalactan from Lycium barbarum as a TLR4-activating adjuvant for nanovaccine-based cancer immunotherapy. Carbohyd Polym. 2026, 373: 124618. (中科院一区，IF=12.5)

2.Zhang J1, Bao CJ1, Zhang XL, Ren YH, Zhao W, Zhang F, Guo S, Duan JA*, Duan JL*, Han X*. Lycium barbarum polysaccharide-based hydrogel as a novel oral colon-targeted drug delivery system for enhanced MSS-CRC treatment by macrophage lipid reprogramming. Adv Funct Mater. 2026: e23769. (中科院一区，IF=19.0)

3.Yao AN1, Liang XF1, Wang ZF, Sha DP, Zhang XL, Liu MQ, Zhao LQ, Liu YN, Guo S, Zhang F, Bao CJ*, Duan JA*, Duan JL*. Acidic Lycium barbarumpolysaccharide as a promising candidate for preventing osteosarcopenia. Food Sci Hum Well. 2026, 15: 9250549. (中科院一区，IF=7.4)

4.Zhao LQ1, Li ZQ1, Liu YF1, Jiang MT1, Liu YN, Zhang XL, Sun YJ, Duan JL*, Bao CJ*, Duan JA*. Ultrasonic complexation with Lycium barbarumpolysaccharide significantly enhances the aqueous solubility and bioavailability of curcumin. Ultrasonics Sonochemistry. 2025, 123: 107673. (中科院一区，IF=9.7)

5.Duan JL1, Zhang XL1, Zhao LQ, Liu YN, Yao AN, Li NG, Duan JA, Bao CJ. Macrophage membrane-camouflaged nanoparticles for targeted drug delivery. Chinese Chem Lett. 2025, 111610. （中科院一区，IF=8.9）

6.Liu MQ1, Bao CJ1, Liang XF, Ji XY, Zhao LQ, Yao AN, Guo S, Duan JL*, Zhao M*, Duan JA*. Specific molecular weight of Lycium barbarum polysaccharide for robust breast cancer regression by repolarizing tumor-associated macrophages. Int J Biol Macromol. 2024, 261 : 129674. （中科院二区，IF=8.5）

7.Duan JL1, Liu MQ1, Liu YN1, Liang XF, Cao C, Yao AN, Zhao LQ, Guo S, Qian DW, Bao CJ*, Zhao M*, Duan JA*. Comparative study on physicochemical characterization and immunomodulatory activities of neutral and acidic Lycium barbarum polysaccharides. Biomed Pharmacother. 2024, 181: 117659. （中科院二区，IF=6.9）

8.Bao CJ1, Duan JL1, Xie Y1, Feng XP, Cui W, Chen SY, Li PS, Liu YX, Wang JL, Wang GL, Lu WL*. Bioorthogonal engineered virus-like nanoparticles for efficient gene therapy. Nanomicro Lett. 2023, 15(1): 197. （中科院一区，IF=31.6）

9.Chen Y1, Bao C1, Duan J1, Xie Y*, Lu W*. Overcoming biological barriers by virus-like drug particles for drug delivery. Adv Drug Deliver Rev. 2023, 203: 115134. （中科院一区，IF=16.1）

10.Duan JL1, Bao CJ1, Xie Y1, Guo HT, Liu YX, Li JW, Liu R, Li PS, Bai J, Yan Y, Mu LM, Li XQ, Wang GL, Lu WL*. Targeted core-shell nanoparticles for precise CTCF gene insert in treatment of metastatic breast cancer. Bioact Mater. 2022, 11: 1-14. （中科院一区，IF=18.9）

获得奖项与荣誉
其他成果


南中医药学院南中医药学院学子南中医药学院研究生